Compare Stocks: BTMD, XGN, LFMD, and JYNT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$1.55	$1.92	$1.27 ▼ $3.58	$55.51M	1.6	345,083 shs	77,387 shs
JYNT Joint	$8.32	$8.58	$7.50 ▼ $10.74	$117.65M	1.05	69,842 shs	52,911 shs
LFMD LifeMD	$3.08	$3.81	$2.56 ▼ $7.32	$148.46M	2.04	688,067 shs	604,671 shs
XGN Exagen	$7.58	$5.84	$2.59 ▼ $12.23	$183.66M	2.1	297,114 shs	138,170 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	0.00%	-1.59%	+4.39%	-33.97%	-55.35%
JYNT Joint	0.00%	-1.30%	-0.12%	+1.46%	-21.80%
LFMD LifeMD	0.00%	-1.91%	-13.48%	-38.65%	-49.17%
XGN Exagen	0.00%	+2.57%	+10.33%	+80.48%	-21.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$1.55	$1.92	$1.27 ▼ $3.58	$55.51M	1.6	345,083 shs	77,387 shs
JYNT Joint	$8.32	$8.58	$7.50 ▼ $10.74	$117.65M	1.05	69,842 shs	52,911 shs
LFMD LifeMD	$3.08	$3.81	$2.56 ▼ $7.32	$148.46M	2.04	688,067 shs	604,671 shs
XGN Exagen	$7.58	$5.84	$2.59 ▼ $12.23	$183.66M	2.1	297,114 shs	138,170 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	0.00%	-1.59%	+4.39%	-33.97%	-55.35%
JYNT Joint	0.00%	-1.30%	-0.12%	+1.46%	-21.80%
LFMD LifeMD	0.00%	-1.91%	-13.48%	-38.65%	-49.17%
XGN Exagen	0.00%	+2.57%	+10.33%	+80.48%	-21.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	2.50	Moderate Buy	$2.50	61.81% Upside
JYNT Joint	2.00	Hold	N/A	N/A
LFMD LifeMD	2.70	Moderate Buy	$7.57	145.83% Upside
XGN Exagen	2.89	Moderate Buy	$9.63	26.98% Upside

Current Analyst Ratings Breakdown

Latest BTMD, XGN, LFMD, and JYNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	JYNT Joint	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/17/2026	LFMD LifeMD	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2026	BTMD biote	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/13/2026	JYNT Joint	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
8/10/2026	BTMD biote	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$2.00 ➝ $1.50
8/7/2026	XGN Exagen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	LFMD LifeMD	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$5.00
8/7/2026	BTMD biote	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$2.50 ➝ $2.00
8/7/2026	LFMD LifeMD	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$10.00 ➝ $9.00
8/6/2026	LFMD LifeMD	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
8/6/2026	LFMD LifeMD	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$192.22M	0.29	$0.58 per share	2.66	($1.40) per share	-1.10
JYNT Joint	$54.90M	2.14	$0.10 per share	85.54	$1.01 per share	8.24
LFMD LifeMD	$194.05M	0.77	N/A	N/A	$0.48 per share	6.42
XGN Exagen	$66.57M	2.76	N/A	N/A	$0.77 per share	9.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$27.05M	$0.11	14.05	9.09	N/A	3.19%	-22.33%	12.10%	11/4/2026 (Estimated)
JYNT Joint	$2.91M	$0.27	30.81	13.21	N/A	6.49%	12.02%	3.47%	11/5/2026 (Estimated)
LFMD LifeMD	$14.35M	-$0.05	N/A	N/A	N/A	0.10%	-168.23%	-31.27%	11/11/2026 (Estimated)
XGN Exagen	-$19.95M	-$0.81	N/A	N/A	N/A	-26.61%	-104.46%	-28.93%	11/3/2026 (Estimated)

Latest BTMD, XGN, LFMD, and JYNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	JYNT Joint	$0.0467	$0.05	+$0.0033	$0.05	$14.57 million	$15.18 million
8/5/2026	Q2 2026	BTMD biote	$0.0267	-$0.23	-$0.2567	-$0.23	$46.12 million	$44.23 million
8/5/2026	Q2 2026	LFMD LifeMD	-$0.1457	-$0.16	-$0.0143	-$0.16	$49.16 million	$47.28 million
8/4/2026	Q2 2026	XGN Exagen	-$0.1914	-$0.13	+$0.0614	-$0.13	$17.80 million	$19.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
JYNT Joint	N/A	N/A	N/A	N/A	N/A
LFMD LifeMD	N/A	N/A	N/A	N/A	N/A
XGN Exagen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	1.43	0.82
JYNT Joint	N/A	1.83	1.83
LFMD LifeMD	N/A	0.90	0.84
XGN Exagen	1.96	3.18	3.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
JYNT Joint	76.88%
LFMD LifeMD	35.52%
XGN Exagen	75.25%

Insider Ownership

Company	Insider Ownership
BTMD biote	32.40%
JYNT Joint	30.20%
LFMD LifeMD	17.22%
XGN Exagen	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	35.93 million	24.29 million	Not Optionable
JYNT Joint	320	14.14 million	9.87 million	Optionable
LFMD LifeMD	230	48.20 million	39.90 million	Optionable
XGN Exagen	220	24.23 million	21.71 million	Optionable

BTMD, XGN, LFMD, and JYNT Headlines

Recent News About These Companies

BlackRock Inc. Purchases Shares of 142,625 Exagen Inc. $XGN

September 7 at 3:44 AM | marketbeat.com

Man Group plc Takes $778,000 Position in Exagen Inc. $XGN

September 4 at 4:40 AM | marketbeat.com

Flputnam Investment Management Co. Acquires New Position in Exagen Inc. $XGN

August 31, 2026 | marketbeat.com

Exagen Inc. (NASDAQ:XGN) Receives Average Rating of "Moderate Buy" from Analysts

August 27, 2026 | americanbankingnews.com

Exagen Inc. (NASDAQ:XGN) Given Average Rating of "Moderate Buy" by Brokerages

August 27, 2026 | marketbeat.com

GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN

August 18, 2026 | marketbeat.com

Exagen (XGN) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Exagen: The Path To Profitability Just Became More Credible

August 5, 2026 | seekingalpha.com

Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability

August 4, 2026 | finance.yahoo.com

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

August 4, 2026 | seekingalpha.com

Exagen Inc. Reports Second Quarter 2026 Financial Results

August 4, 2026 | markets.businessinsider.com

Exagen reports record second-quarter 2026 revenue and raises full-year guidance

August 4, 2026 | msn.com

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

August 4, 2026 | quiverquant.comQ

Exagen reports record Q2 revenue of $19.9 million

August 4, 2026 | quiverquant.comQ

Exagen Inc. to Participate in Upcoming Investor Conference

July 28, 2026 | globenewswire.com

Exagen: A Small Diagnostics Company Approaching An Inflection Point

July 23, 2026 | seekingalpha.com

Exagen to Announce Second Quarter Financial Results on August 4, 2026

July 21, 2026 | markets.businessinsider.com

Exagen Shareholders Approve Directors, Auditor and Pay Package

June 9, 2026 | tipranks.com

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD, XGN, LFMD, and JYNT Company Descriptions

biote NASDAQ:BTMD

$1.54 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Joint NASDAQ:JYNT

$8.32 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

LifeMD NASDAQ:LFMD

$3.08 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Exagen NASDAQ:XGN

$7.58 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTMD, XGN, LFMD, and JYNT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTMD, XGN, LFMD, and JYNT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTMD, XGN, LFMD, and JYNT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD, XGN, LFMD, and JYNT Company Descriptions

biote NASDAQ:BTMD

Joint NASDAQ:JYNT

LifeMD NASDAQ:LFMD

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTMD, XGN, LFMD, and JYNT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTMD, XGN, LFMD, and JYNT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTMD, XGN, LFMD, and JYNT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTMD, XGN, LFMD, and JYNT Company Descriptions

biote NASDAQ:BTMD

Joint NASDAQ:JYNT

LifeMD NASDAQ:LFMD

Exagen NASDAQ:XGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools